The national shortage of oseltamivir, the generic of common flu drug Tamiflu, has seen a slight reprieve despite flu hospitalizations hiking and Tamiflu demand spiking weeks earlier than normal.
As of Dec. 2, 10 oseltamivir products from five drugmakers were in short supply, according to the American Society of Health-System Pharmacists. The update is a minor improvement from a month ago when there were 12 products from six companies part of the dearth.
The back-ordered and allocated products include three from Amneal Pharmaceuticals, three from Camber Pharmaceuticals, two from Macleods Pharma, one from Zydus Lifesciences and one from Teva Pharmaceuticals.